aTyr Pharma, Inc.: aTyr Pharma Announces Fourth Quarter and Full Year 2024 Results and Provides Corporate Update
Topline data from Phase 3 EFZO-FIT study of efzofitimod in pulmonary sarcoidosis expected in the third quarter of 2025. Fourth positive DSMB review for efzofitimod in Phase 3 EFZO-FIT study reinforces ...
aTyr Pharma Announces Fourth Quarter and Full Year 2024 Results and Provides Corporate Update
Topline data from Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis expected in the third quarter of 2025. Fourth positive DSMB review for efzofitimod in Phase 3 EFZO-FIT™ study ...
Cellectis Reports Financial Results for the Fourth Quarter and Full Year 2024 and Provides a Business Update
UCART22 Phase 1 dataset and late-stage development strategy expected in the third quarter of 2025; Orphan Drug Designation (ODD) and Rare ...
Gossamer Bio Announces Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update
Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and ...
PhillyVoice40m
The worst Sixers lineup of the last 10 years
The Sixers have fielded plenty of horrid teams in the last decade, but one group from December 2015 takes the cake.
Seres Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
Recent FDA feedback received on SER-155 allogeneic hematopoietic stem cell transplant (allo-HSCT) next study provides support for the proposed ...
Le Lézard21h
Epirium Bio to Present MF-300 Preclinical Data at the International Conference on Frailty and Sarcopenia Research
Epirium Bio Inc. (Epirium), a clinical stage biopharmaceutical company advancing medicines for neuromuscular and fibrotic diseases, today announced the upcoming presentation of two scientific posters ...
Seres Therapeutics, Inc.: Seres Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
Recent FDA feedback received on SER-155 allogeneic hematopoietic stem cell transplant (allo-HSCT) next study provides support for the proposed primary efficacy endpoint of reduction in bloodstream inf ...
Medindia21h
Virax Biolabs Presents Data on T-Cell Dysfunction in Post-acute Infection Syndromes at the 19th World Immune Regulation Meeting
Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative biotechnology company focused on the detection of immune responses and diagnosis of viral diseases, today announced ...
Le Lézard21h
Precigen to Announce Full Year 2024 Financial Results and Provide Business Updates on March 19th
Precigen, Inc. , a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced the Company will release full year ...
Clinical Advisor13h
Pediatric Clinic Implements New Screening Tool, Improving Childhood Obesity Evaluation
A new screening intervention in the primary care setting can improve the identification and management of obesity risk in pediatric patients, according to a poster presented at the National ...
‘It’s not Times Square’: Woollahra, Rose Bay residents erupt over bus stop billboards
Tensions have erupted in one of Sydney’s most picturesque communities between local council and furious residents over the installation of “huge, ugly bus shelters” across the district.